Tectonic Therapeutic, Inc.
TECXNasdaq
$32.60
↑ +6.4%Jul 17 close · end-of-day
Price
1Y↑ +44.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$611.9M
Enterprise Value
$375.0M
P/E
—
P/S
—
P/B
2.7
EV/EBITDA
—
PEG
—
FCF Yield
-10.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$74.2B
Free Cash Flow (TTM)
-$65.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-32185.3%
ROIC
—
Debt / Equity
—
Net Cash
$236.9M
Return 1Y
+40.0%
Company profile
Tectonic is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-Protein Coupled Receptors. We have developed a proprietary technology platform called GEODe™ to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease, by addressing challenges that have limited the pace of innovation in this field. Our focus is on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life.
- CEO
- Alise Reicin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- Massachusetts
- Website
- tectonictx.com
Management & directors
- Mcnamara PeterChief Scientific Officer
- Reicin AliseChief Executive Officer
- Ruddy Marcella K.Chief Medical Officer
- Lochner DanielChief Financial Officer
- Schwabish MarcChief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
TECX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.34↑ +44.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$120.2M | -$118.8M | -$105.4M | -$44.6M | -$58.0M | -$84.0M |
| Net income | -$119.7M | -$119.1M | -$105.9M | -$42.8B | -$58.0B | -$74.2B |
| Diluted EPS | — | -$2.78 | -$2.42 | -$33.76 | -$6.83 | -$4.05 |
| Operating cash flow | -$98.8M | -$98.0M | -$97.2M | -$40.7M | -$59.1M | -$60.1M |
| Free cash flow | -$100.0M | -$100.5M | -$97.5M | -$41.0M | -$59.2M | -$60.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$11.4M | -$19.6M | -$14.0M | -$18.3M | -$22.3M | -$21.9M | -$21.5M | -$27.3M |
| Net income | -$12.7M | -$17.7M | -$57.9B | -$15.9M | -$20.0M | -$19.0M | -$74.1B | -$25.2M |
| Diluted EPS | -$4.34 | -$1.20 | $9.68 | -$0.93 | -$1.07 | -$1.02 | -$1.03 | -$1.34 |
| Operating cash flow | -$13.4M | -$19.6M | -$16.8M | -$13.1M | -$14.7M | -$17.8M | -$14.5M | -$18.4M |
| Free cash flow | -$13.4M | -$19.8M | -$16.8M | -$13.1M | -$14.7M | -$18.0M | -$14.5M | -$18.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Apr 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | McNamara Peter· Chief Scientific Officer | Sale | 172 | $35.00 | $6,020.00 | filing |
| 2026-06-30 | McNamara Peter· Chief Scientific Officer | Option exercise | 172 | $14.71 | $2,530.12 | filing |
| 2026-06-20 | REICIN ALISE· Chief Executive Officer | Tax withholding | 924 | $30.34 | $28,034.16 | filing |
| 2026-05-04 | Ruddy Marcella K.· Chief Medical Officer | Sale | 1,065 | $30.00 | $31,950.00 | filing |
| 2026-04-01 | Ruddy Marcella K.· Chief Medical Officer | Sale | 1,000 | $31.05 | $31,050.00 | filing |
| 2026-03-06 | Ruddy Marcella K.· Chief Medical Officer | Sale | 10,000 | $30.00 | $300,000.00 | filing |
| 2026-03-06 | McNamara Peter· Chief Scientific Officer | Sale | 6,047 | $30.00 | $181,410.00 | filing |
| 2026-03-06 | McNamara Peter· Chief Scientific Officer | Sale | 215 | $35.00 | $7,525.00 | filing |
| 2026-03-06 | McNamara Peter· Chief Scientific Officer | Option exercise | 2,500 | $2.38 | $5,950.00 | filing |
| 2026-03-06 | McNamara Peter· Chief Scientific Officer | Option exercise | 215 | $14.71 | $3,162.65 | filing |
| 2026-03-04 | McNamara Peter· Chief Scientific Officer | Sale | 1,650 | $25.00 | $41,250.00 | filing |
| 2026-03-04 | McNamara Peter· Chief Scientific Officer | Award | 23,000 | $0.00 | $0.00 | filing |
| 2026-03-04 | Schwabish Marc· Chief Business Officer | Award | 19,500 | $0.00 | $0.00 | filing |
| 2026-03-04 | REICIN ALISE· Chief Executive Officer | Award | 76,500 | $0.00 | $0.00 | filing |
| 2026-03-04 | Lochner Daniel· Chief Financial Officer | Award | 26,500 | $0.00 | $0.00 | filing |
| 2026-03-04 | Ruddy Marcella K.· Chief Medical Officer | Award | 26,500 | $0.00 | $0.00 | filing |
| 2026-03-03 | McNamara Peter· Chief Scientific Officer | Sale | 1,649 | $22.06 | $36,376.94 | filing |
| 2026-02-11 | REICIN ALISE· Chief Executive Officer | Buy | 2,500 | $21.10 | $52,750.00 | filing |
| 2026-02-11 | REICIN ALISE· Chief Executive Officer | Buy | 2,500 | $21.10 | $52,750.00 | filing |
| 2026-02-10 | Lochner Daniel· Chief Financial Officer | Buy | 6,000 | $21.61 | $129,660.00 | filing |
| 2026-02-10 | Schwabish Marc· Chief Business Officer | Option exercise | 4,500 | $2.38 | $10,710.00 | filing |
| 2026-02-04 | REICIN ALISE· Chief Executive Officer | Tax withholding | 4,104 | $23.22 | $95,294.88 | filing |
| 2026-02-04 | Lochner Daniel· Chief Financial Officer | Tax withholding | 2,077 | $23.22 | $48,227.94 | filing |
| 2026-02-04 | Ruddy Marcella K.· Chief Medical Officer | Tax withholding | 2,064 | $23.22 | $47,926.08 | filing |
| 2026-02-04 | McNamara Peter· Chief Scientific Officer | Tax withholding | 1,748 | $23.22 | $40,588.56 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.